The past year in osteoporosis: anabolic and antiresorptive drugs, monitoring, fracture care and prevention, each summarised in the MedShorts 360 format with its date and source.
OrthopaedicsA new ‘expected change’ approach shows CTX and PINP at 3 months reliably identify response, while BMD at 2 years often does not.
OrthopaedicsIn a nationwide matched cohort of high-risk women, both anabolic drugs increased BMD at all sites and improved 3D hip structure over 12 months.
OrthopaedicsA meta-analysis found no significant effects of GLP-1 RAs on bone or joint outcomes; lean mass reductions mostly reflected weight loss.
OrthopaedicsIn 48 older adults with pelvic fractures, abaloparatide did not improve CT healing, pain or function at 3 months versus placebo.
OrthopaedicsIn a 10-year real-world cohort, continuous denosumab produced sustained BMD gains, and prior bisphosphonate use did not reduce long-term response.
OrthopaedicsPerioperative anabolic therapy was associated with lower proximal junctional kyphosis after adult spinal deformity surgery.
OrthopaedicsExercise improved BMD at the spine, femoral neck and total body, with benefits peaking around 1,100 MET-min a week for the spine.
OrthopaedicsAcross seven RCTs with 2,251 women, biosimilar and reference denosumab gave equivalent lumbar spine BMD gains and similar fractures and immunogenicity.
OrthopaedicsIn patients with rheumatic disease on steroids, switching from bisphosphonates to romosozumab gave numerically larger BMD increases at 12 months.
OrthopaedicsA meta-analysis supports using teriparatide before or after bisphosphonates when indicated.
OrthopaedicsIn 192 women with severe osteoporosis, romosozumab raised spine and hip BMD, with much larger gains in those not previously treated.
OrthopaedicsVertebral augmentation generally ranked above conservative care for pain, but no single technique was best on every outcome.
OrthopaedicsExperts recommend non-renally cleared markers such as bone-specific ALP and TRAP5b to evaluate and treat bone fragility in CKD.
OrthopaedicsA Lancet Healthy Longevity meta-analysis found bisphosphonates did not affect healing time or rate, and teriparatide shortened time to union.
OrthopaedicsIn 83,147 Israeli women, HT initiated after age 65 was associated with more cancer and vascular events, supporting guidance against late initiation.
OrthopaedicsAcross 69 trials and 153,902 adults not on osteoporosis drugs, supplements had little to no clinically meaningful effect on fractures or falls.
OrthopaedicsCreatine ≥5 g/day with resistance training improved lean mass and leg-press strength in postmenopausal women; BMD was unchanged.
OrthopaedicsAcross six RCTs and 4,151 participants, GI adverse events were 20.2% with alendronate and 18.3% with risedronate, not significantly different.
OrthopaedicsIndividual data from 1,112 patients show modest lumbar spine bone loss with ≤7.5 mg/day prednisone, without more fractures.
OrthopaedicsEating 50–100 g of prunes daily showed a borderline benefit at the lumbar spine in postmenopausal women.
OrthopaedicsA lifetime Markov model found biosimilar denosumab likely cost-effective against alendronate, risedronate, ibandronate and zoledronic acid at $150,000 per QALY.
OrthopaedicsIn 10,811 matched treatment-naive pairs, denosumab with any delay in the second dose was linked to more vertebral fractures than annual zoledronate.
OrthopaedicsNetazepide raised gastrin and lowered pepsinogens as expected, but did not change the bone resorption marker CTX over 90 days.
OrthopaedicsOsteopenia or osteoporosis was consistently associated with coronary calcification, especially at the femoral neck (OR 2.52).
OrthopaedicsAn abbreviated romosozumab course followed by denosumab was non-inferior to 12 months of romosozumab for total hip BMD gain in high-risk postmenopausal women.